On May 31st, Sanofi announced that its infant nasal spray respiratory syncytial virus attenuated live vaccine (RSVt vaccine, SP0125) has been approved by the Drug Evaluation Center of the National Me ...

On June 3rd, Southern Finance and Economics reported that Sanofi announced that its attenuated live vaccine for respiratory syncytial virus (RSVt vaccine, SP0125) for infants and young children has b ...